Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib (ABL001) in CML and Ph+ ALL
NCT02081378Phase 1Completed
- Sponsor
- Novartis
- Start
- Apr 2014
- Primary completion
- Jun 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 1, open-label trial of asciminib in chronic myeloid leukemia (CML) and Acute lymphoblastic leukemia, Philadelphia chromosome positive (5 arms), sponsored by Novartis. Primary endpoint: Incidence of dose limiting toxicities at 28 days. Started Apr 2014; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT02081378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081378.